AARD
What one share of Aardvark Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.
Aardvark Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$3.20 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$3.18 |
| Cash and investments | $3.37 |
| Book value | $3.42 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$5.15 | $0.03 | −$4.55 | — | −$13.44 |
| 2025 | $0.00 | −$2.93 | $0.00 | −$2.77 | — | $4.89 |